Literature DB >> 1321291

Packaging system for rapid production of murine leukemia virus vectors with variable tropism.

N R Landau1, D R Littman.   

Abstract

A method for rapidly producing helper-free murine leukemia virus (MLV) without using packaging cell lines is described. Viruses bearing ecotropic or amphotropic MLV or Rous sarcoma virus envelope glycoprotein and containing various retroviral vector genomes have been prepared with titers 30 to 40-fold higher than those produced by transient transfection of standard packaging cells. This system can be used to alter the cellular tropism of MLV by incorporating other envelope glycoproteins and to prepare retroviral vector stocks without establishing stable producer cell lines. This method will be particularly useful for preparing viruses that encode toxic proteins and for the rapid analysis of panels of mutant envelope glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321291      PMCID: PMC241381     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  12 in total

1.  Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs.

Authors:  J M Turner; M H Brodsky; B A Irving; S D Levin; R M Perlmutter; D R Littman
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

2.  Expression of human class II major histocompatibility complex antigens using retrovirus vectors.

Authors:  A J Korman; J D Frantz; J L Strominger; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

3.  Gene expression from both intronless and intron-containing Rous sarcoma virus clones is specifically inhibited by anti-sense RNA.

Authors:  L J Chang; C M Stoltzfus
Journal:  Mol Cell Biol       Date:  1985-09       Impact factor: 4.272

4.  Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo.

Authors:  B C Guild; M H Finer; D E Housman; R C Mulligan
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

5.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

6.  Lack of competition results in efficient packaging of heterologous murine retroviral RNAs and reticuloendotheliosis virus encapsidation-minus RNAs by the reticuloendotheliosis virus helper cell line.

Authors:  J E Embretson; H M Temin
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

7.  Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene.

Authors:  L L Stuve; S Brown-Shimer; C Pachl; R Najarian; D Dina; R L Burke
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

8.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

9.  Human cells infected with retrovirus vectors acquire an endogenous murine provirus.

Authors:  D T Scadden; B Fuller; J M Cunningham
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

10.  Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences.

Authors:  P T Kirschmeier; G M Housey; M D Johnson; A S Perkins; I B Weinstein
Journal:  DNA       Date:  1988-04
View more
  114 in total

1.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.

Authors:  A L Boerger; S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation.

Authors:  Q X Li; J M Robbins; P J Welch; F Wong-Staal; J R Barber
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

3.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

4.  Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

Authors:  S Yi; M S Tsao
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

5.  Induction of a secreted protein by the myxoid liposarcoma oncogene.

Authors:  M Kuroda; X Wang; J Sok; Y Yin; P Chung; J W Giannotti; K A Jacobs; L J Fitz; P Murtha-Riel; K J Turner; D Ron
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

6.  Stress- and cell type-dependent regulation of transfected c-Jun N-terminal kinase and mitogen-activated protein kinase kinase isoforms.

Authors:  L Butterfield; E Zentrich; A Beekman; L E Heasley
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

7.  An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor.

Authors:  J L Blond; D Lavillette; V Cheynet; O Bouton; G Oriol; S Chapel-Fernandes; B Mandrand; F Mallet; F L Cosset
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest.

Authors:  G S Dbaibo; M Y Pushkareva; S Jayadev; J K Schwarz; J M Horowitz; L M Obeid; Y A Hannun
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus.

Authors:  M Suomalainen; H Garoff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.